49OIMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC). (17th December 2018) - Califano, R; Każarnowicz, A; Karaseva, N; Sánchez, A; Liu, S V; Horn, L; Quach, C; Yu, W; Kabbinavar, F; Lam, S; Mansfield, A